Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment-Reference-Cited by-同舟云学术

Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

Published:2018-10-19 Issue:2 Volume:75 Page:217-226
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Kosloski Matthew P.,Wang Haoyu,Pugatch David,Mensa Federico J.,Gane Edward,Lawitz Eric,Marbury Thomas C.,Preston Richard A.,Kort Jens,Liu Wei

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s00228-018-2576-4/fulltext.html

Reference38 articles.

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529–538

2. Lu M, Gordon SC, Li J, Rupp LB, Zhou Y, Moorman AC et al (2016) Hepatitis C complications: prevalence and disparities in a large US cohort 2006–2014. Hepatology 64. Plenary and Parallel Sessions (Abstract 180)

3. AASLD-IDSA (2017) HCV guidance: recommendations for testing, managing, and treating hepatitis. Available from: https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_September_21_2017_h.pdf

4. EASL (2018) EASL recommendations on treatment of hepatitis C. Available from: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-on-treatment-of-hepatitis-c-2018

5. AbbVie (2017) Maviret (glecaprevir and pibrentasvir tablets) . Summary of product characteristics. Maidenhead, United Kingdom

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The solution structure of macrocyclic glecaprevir and its conformational adaptation mechanism towards antitumor targets;Journal of Molecular Structure;2025-02

2. Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review;Expert Opinion on Pharmacotherapy;2024-08-12

3. Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of the direct acting antivirals glecaprevir and pibrentasvir in plasma;Journal of Pharmaceutical and Biomedical Analysis;2023-10

4. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study;Hepatology International;2023-06-05

5. Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers;International Journal of Molecular Sciences;2023-02-25